In June 2022, Uzbek scientists registered and produced a new anticancer drug.
According to the Academy of Sciences of Uzbekistan, radiopharmaceutical preparation ‘Lutetium-177’ effectively treats only one kind of cancer, prostate cancer, observed mainly in elderly men.
At the same time, therapeutic effects on metastases in other body parts were observed at the fourth and fifth doses.
The Academy of Sciences stated that other websites in an abbreviated form had reprinted the interview, omitting the widely spread information.
‘Thus, the public thought that this drug cures all kinds of cancer,’ the statement reads.
The academy also notes that ‘Lutetium-177’ is not sold in pharmacies but delivered to medical institutions.
Comments (0)